Monday, 18 July 2011

MDS Mid-year Double Bill

By Sharon Siddique
MDS President

Dear MDS members,
 

We will be having a mid-year double bill in August. The afternoon’s programme will begin with a talk and question and answer session by our MDS advisor, Dr Au Eong Kah Guan. This will be followed by our AGM, which will include a review of MDS activities since our previous AGM, held on 10 July 2010. Members are encouraged to attend to share your views on past activities and suggestions for MDS activities in 2011/2012.

Talk: “Latest Trends in the Management of Macular Degeneration” 


Speaker: Dr Au Eong Kah Guan


Date: Saturday 27 August 2011


Time: 2pm – 2.45pm


Venue: Seminar Room, Alexandra Hospital, Alexandra Road




Tea Break: 2.45pm – 3.15pm



=====================

Agenda of the 4th AGM of MDS


Welcome by MDS President, Sharon Siddique


Annual Report 2010/2011


Financial Report 2010/2011


Overview of MDS online: website, blog and Facebook


Discussion of future activities 2011/2012

Please indicate your attendance by either telephoning Anne (62387387), or sending an email to alleyes@singnet.com.sg.
 

We hope to see you on the 27th of August!



Monday, 11 July 2011

Bionic spectacles on the way

The Daily Mail
July 5, 2011
By Fiona Macrae

Bionic spectacles could soon be on sale to help hundreds of thousands of blind people ‘see’. Oxford University researchers are developing ‘smart spectacles’ that use tiny cameras and a pocket computer to alert wearers to objects and people ahead.



They will make it easier for the blind to navigate shopping centres and busy train stations, and could even allow them to ‘read’ bus numbers and the computerised displays on cash machines. The lightweight, inexpensive glasses, which could be ready for general sale as early as 2014 if tests are successful, would be suitable for most of the 300,000 Britons who are registered blind.

Elderly people with age-related macular degeneration are likely to be the biggest beneficiaries. Previous attempts to create such a device have resulted in large dark glasses with clunky cameras and bulky computers. But advances in technology mean it should be possible to create bionic spectacles that look almost indistinguishable from standard glasses.

Importantly, a price tag of less than £1,000 should make them affordable, the Royal Society’s Summer Science Exhibition heard. Dr Stephen Hicks, a clinical neuroscience researcher who is being funded by the Department of Health, said: ‘It is satisfying to think that we will be able to produce this at a cost that is going make it available to the people who will benefit the most.’

Dr Hicks has completed the basic research and is now working on prototype spectacles.

He envisages transparent glasses with lenses studded with small light-emitting diodes and cameras the size of a pinhead at the outside top corners of the frame. The cameras will take in the information the eyes should see and send it down a cable to a mobile phone-sized computer in the wearer’s pocket. The computer will process the information and simplify it into a pattern of dots. The LEDs in the lenses then light up in that pattern, giving the wearer vital information about what lies ahead.

A flickering light could mean there is a person ahead, while a solid block might signify an object such as a flight of stairs. While such information may seem unimpressive to the sighted, it could allow those who have lost much of their vision to regain sufficient independence to go shopping alone or take public transport.

Adding in an earpiece could allow more complex information to be transmitted. For instance, the cameras could capture bus numbers or information on railway departure boards to be analysed by the computer. Once processed, the information would be passed on to the wearer via a voice in their ear.

In time, the same principle could be used to help blind people to ‘see’ the screens on cash machines outside banks or ticket dispensers at train stations. The bionic spectacles rely on the wearer being able to perceive light, so will not be suitable for those who are totally blind. But most of those registered blind, including many sufferers of age-related macular degeneration, still have some vision.

Dr Hicks plans to do small-scale laboratory tests on the blind this year, before enrolling 120 people in a two-year trial that will explore the use of the spectacles in shopping centres and at home.

Friday, 1 July 2011

US advisers back Eylea

June 17, 2011
By Anna Yukhananov

COLLEGE PARK, Maryland (Reuters) - A new eye medicine from Regeneron Pharmaceuticals Inc and Bayer AG is safe and effective for treating a common cause of vision loss, a panel of U.S. experts said on Friday. The Food and Drug Administration advisory panel voted unanimously to recommend Eylea as a treatment for the most serious form of macular degeneration that affects at least 1.5 million Americans.

The advisers also said the injected drug could be given once every two months, giving it an edge over the typical monthly dosing of its chief competitor, Lucentis, from Roche Holding AG.

"The data is very compelling for equivalence (with Lucentis)," said Dr. Lynn Gordon, a panel member and associate professor at the University of California in Los Angeles.

The FDA usually follows the advice of its advisory panels and is expected to rule on Eylea by August 20. Regeneron shares, halted much of Friday pending the advisory panel decision, lost 4.8 percent on Nasdaq to close at $54.02. Jason Kantor of RBC Capital Markets said Regeneron's share price had reflected an expected favorable opinion, so the decline was likely a case of "selling on the news."

Kantor predicted the drug would fare well, but said the main reason to own Regeneron is its array of antibodies being developed for other diseases in partnership with French drugmaker Sanofi SA. Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with the wet form the most serious. Some 11 million Americans have signs of AMD. Piper Jaffray analyst Edward Tenthoff sees Regeneron taking 25 percent of the U.S. market by 2016, with annual sales of $1.2 billion.

CHEAPER CANCER DRUG

Eylea and Lucentis could face competition from Roche's cancer drug Avastin, a much less expensive medicine that is often used by doctors to treat macular degeneration even though it has not been approved by the FDA for that purpose. The amount of Avastin needed for an eye injection costs only around $50, against a U.S. price of $1,950 for Lucentis and probably a similar price for Eylea. All three drugs work in a similar way. An April study showed Avastin was as effective as Lucentis, though it had more side effects.

Eylea's advantage over both rivals may be its two-month dosing. In clinical trials, Regeneron showed that Eylea injected into the eye every two months was as effective as monthly doses of Lucentis. The committee said monthly monitoring of patients receiving Eylea was not necessary.

"I think many of my patients are looking for something they can take less often, and that's the exciting possibility of Eylea," said Dr. Jeffrey Heier, a clinical instructor of ophthalmology at Harvard Medical School who spoke on behalf of Regeneron.

Regeneron has full marketing rights to the drug in the United States and would share overseas profits equally with Germany's Bayer if Eylea wins regulatory approval in other countries. "It's a particularly proud day for us because few companies can go from the discovery of the molecule and take it to this point," said Regeneron Chief Executive Officer Leonard Schleifer.

"We started out as good scientists and hopefully we can become good manufacturers too."